New drug indication approval - November 2022
Product Name
|
ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL
|
Active Ingredient
|
Trastuzumab deruxtecan
|
Product Registrant
|
ASTRAZENECA SINGAPORE PTE LTD
|
Date of Approval
|
30/11/2022
|
Indications:
ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen.
|
Healthcare professional, Industry member, Therapeutic Products
Published:
New Drug Indication Approvals